WAY 125984

Drug Profile

WAY 125984

Latest Information Update: 06 Oct 2011

Price : $50

At a glance

  • Originator Wyeth
  • Class Anti-inflammatories
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation; Rheumatic disorders

Most Recent Events

  • 07 Sep 1998 No-Development-Reported for Inflammation in USA (Unknown route)
  • 07 Sep 1998 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
  • 13 Nov 1996 A preclinical study has been added to the Inflammation and Rheumatic Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top